Cohance Lifesciences’ consensus analyst price target saw a modest decrease to ₹1213, as both net profit margin and future P/E remained virtually unchanged, indicating stable fundamentals despite the downward revision in fair value.
What's in the News
- Cohance Lifesciences invested USD 10 million to expand cGMP bioconjugation capabilities at its U.S. subsidiary, NJ Bio, enhancing its Antibody-Drug Conjugate (ADC) offering and supporting global innovators from early development to late-phase clinical supply.
- NJ Bio is executing a major ADC program for an existing innovator customer, with discussions underway with three to four additional potential customers as ADC programs shift to cGMP manufacturing.
- A new state-of-the-art cGMP bioconjugation suite at NJ Bio's Princeton facility will boost clinical ADC manufacturing capacity to meet Phase 1 and Phase 2 needs, expected operational by end of FY26.
- Cohance announced an INR 230 million investment in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad, enhancing its capabilities in modified nucleosides and locked nucleic acids (LNA) and expanding GMP capacity up to 700 kg annually.
- The Board of Directors will meet to consider and approve the company's unaudited financial results for the quarter ending June 30, 2025.
Valuation Changes
Summary of Valuation Changes for Cohance Lifesciences
- The Consensus Analyst Price Target has fallen slightly from ₹1246 to ₹1213.
- The Net Profit Margin for Cohance Lifesciences remained effectively unchanged, moving only marginally from 24.58% to 24.17%.
- The Future P/E for Cohance Lifesciences remained effectively unchanged, moving only marginally from 61.65x to 60.68x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.